PATHOPHYSIOLOGY, INVESTIGATIONS, AND TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA

PDF

Published: 2022-02-17

Page: 308-316


OMAR ELSAKA *

Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

MONEER AYMAN NOURELDEAN

Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

MOHAMED ADEL GAMIL

Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

MOSTAFA TAREK GHAZALI

Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

ASHRAF HAMADA ABD AL-RAZIK

Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

DALIA HISHAM

Department of Hematology and Oncology, Faculty of Medicine, Mansoura University, Mansoura Manchester Medical Program (MMMP), Mansoura, Egypt.

*Author to whom correspondence should be addressed.


Abstract

In otherwise healthy children or adults, immune thrombocytopenic purpura (ITP) has a low platelet count, usually less than 100,000, in the presence of common petechiae, bruises, or bleeding. It is explained that there is. ITP is most commonly found in children of all ages, not just adults. This activity describes the role of an inter-expert team in the evaluation and treatment of patients with immune thrombocytopenic purpura (ITP). The aim of this review article is to determine the etiology of immune thrombocytopenic purpura, formulate the patient's unique presentation with ITP, interpret general physical exam findings associated with ITP, and improve coordination of care among international team members. Outcomes will be discussed for patients with ITP.

Keywords: Hematoma, idiopathic thrombocytopenic purpura, petechiae, platelets


How to Cite

ELSAKA, O., NOURELDEAN, M. A., ADEL GAMIL, M., GHAZALI, M. T., ABD AL-RAZIK, A. H., & HISHAM, D. (2022). PATHOPHYSIOLOGY, INVESTIGATIONS, AND TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA. Asian Journal of Advances in Research, 5(1), 308–316. Retrieved from https://mbimph.com/index.php/AJOAIR/article/view/2820

Downloads

Download data is not yet available.

References

Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21; 117(16):4190-207.

Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829- 3866.

Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26;3(22):3780-3817.

Ahn ER, Tiede MP, Jy W, et al. Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: Eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol. 2006;116(1):19-24.

Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007 Apr;21(2 suppl 1):S9-56.

Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015 (1):237-42.

Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017 Jun;16 (6):620-632.

Balagué C, Vela S, Targarona EM, et al. Predictive factors for successful laparoscopic splenectomy in immune thrombocytopenic purpura: study of clinical and laboratory data. Surg Endosc. 2006 Aug;20(8):1208-13.

Beattie JF, Michelson ML, Holman PJ. Acute babesiosis caused by Babesia divergens in a resident of Kentucky. N Engl J Med. 2002 Aug 29;347(9):697-8.

Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004 Dec;83(12):764-8.

Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47.

Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19;355(16):1672-81.

Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev. 2002 Mar. 16(1):31-6.

Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29;377(9763):393-402.

Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005 Oct 1;106(7):2244-51.

Cines DB, Gernsheimer T, Wasser J, Godeau B, Provan D, Lyons R, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015 Sep;102(3): 259-70.

Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?. Curr Opin Hematol. 2007 Nov;14(6):642-6.

Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009 Oct 1;114(14):2861-8.

Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: A systematic review and meta-analysis. J Antimicrob Chemother. 2007 Aug;60(2):237-46.

George JN. Management of immune thrombocytopenia--something old, something new. N Engl J Med. 2010 Nov 11;363(20):1959-61.

Gudbrandsdottir S, Birgens HS, Frederiksen H, Jensen BA, Jensen MK, Kjeldsen L, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013 Mar 14;121(11):1976-81.

Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: A systematic review and meta-analysis. Blood. 2014 Nov 20;124(22):3295-307.

Inaba T, Mizuno M, Take S, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005 Mar;35(3):214-9.

Jamali F, Lemery S, Ayalew K, Robottom S, Robie-Suh K, Rieves D, et al. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Oncology (Williston Park). 2009 Jul;23(8):704-9.

Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018 Nov;183(3):479-490.

Khan LR, Nixon SJ. Laparoscopic splenectomy is a better treatment for adult ITP than steroids--it should be used earlier in patient management. Conclusions of a ten-year follow-up study. Surgeon. 2007 Feb;5(1):3-4, 6-8.

Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet. 2008 Feb 2;371(9610):395-403.

Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010 Nov 11;363(20):1889-99.

Lai SW, Lin HF, Lin CL, Liao KF. Immune thrombocytopenic purpura might be an early hematologic manifestation of undiagnosed human immunodeficiency virus infection. Intern Emerg Med. 2017 Mar;12(2):157-162.

Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835.

Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: A systematic review of the literature and guidance for management. J Pediatr. 2010 Apr;156(4):623-8.

Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: A GIMEMA experience. Blood. 2007 Feb 15;109(4):1401-7.

McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb;83(2):150-4.

Michel M, Rauzy OB, Thoraval FR, et al. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol. 2011 Dec;86(12):980-4.

Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: A nationwide population-based study in France. Blood. 2014 Nov 20;124(22):3308-15.

Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol. 2007 Oct;44(4 suppl 5):S35-45.

Purcell PL, Crary SE, Adix LM, Alder AC, Buchanan GR. Postsplenectomy vascular complications: Feasibility of studying patients with splenectomy following trauma. Am J Hematol. 2009 May;84(5):316-7.

Rajantie J, Zeller B, Treutiger I, Rosthöj S. Vaccination associated thrombocytopenic purpura in children. Vaccine. 2007 Feb 26;25(10):1838-40.

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010 Sep 23;116(12):2127-33.

Rodeghiero F, Frezzato M, Schiavotto C, Castaman G, Dini E. Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura. Haematologica. 1992 May-Jun;77(3):253-6.

Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med. 2004 Sep 27;164(17):1904-7.

Schultz CL, Mitra N, Schapira MM, Lambert MP. Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia. JAMA Pediatr. 2014 Oct;168(10):e142214.

Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008 Jan;99(1):4-13.

Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, et al. Romiplostim in children with immune thrombocytopenia: A phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Jul 2;388 (10039):45-54.